The Electronic Asthma Management System in Pharmacies

NCT07038642 | Enrolling By Invitation

• 1 other identifier: 46441
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this study is to assess the effect of an electronic asthma management system in pharmacies (eAMS-Pharm) on asthma control assessment, asthma medication adjustment, asthma action plan delivery, and prompting for specialist referral in severe asthma. The study assesses the differences on pharmacy processes (affecting both the pharmacy team and patients) and pharmacy-delivered care using an interrupted time-series analysis (six-months before vs. six-months after the introduction of eAMS-Pharm in study pharmacy sites). The eAMS-Pharm uses patient data (asthma control, asthma flare-up risk, and current medications) to provide clinical decision support to pharmacists, empowering them to bridge existing gaps between guideline-recommended asthma care and patient care received.

Conditions

Pharmacy; Asthma Management; Asthma; Computerized Decision Support System

Keywords

Asthma; Pharmacy; Asthma management; Computerized decision support system

Outcome Measures

Primary Outcomes (3)

• Medication adjustments

  Using pharmacist chart review, the investigators will assess the proportion and trend in patients receiving medication adjustments

  12 months, broken into individual time series periods

• Asthma control assessment

  Using pharmacist chart review, the investigators will assess the proportion and trend of patients receiving asthma control assessment by guideline criteria

  12 months, broken into individual time series periods

• Asthma action plan creation

  Using pharmacist chart review, the investigators will assess the proportion and trend of asthma action plans being created for patients

  12 months, broken into individual time series periods

Secondary Outcomes (15)

• System usage: virtual and in-person visit frequency

  6 months

• System usage: content access frequency

  6 months

• System usage: patient engagement frequency, by method

  6 months

• System usage: time required for access and documentation

  6 months

• Quantitative patient Likert-Scale questionnaire

  6 months

Study Arms (2)

Control - None

NO INTERVENTION

A retrospective, pharmacy chart review will assess pharmacy-delivered care in the six-month pre-intervention period.

Intervention - The Electronic Asthma Management System in Pharmacies (eAMS-Pharm)

ACTIVE COMPARATOR

Throughout the intervention period, the eAMS-Pharm will be provided to pharmacists/RPhTs/assistants/students (for use in eligible patients).

Behavioral: Pharmacy Clinical Decision Support System for Asthma Management

Interventions

Pharmacy Clinical Decision Support System for Asthma Management BEHAVIORAL

A pharmacy clinical decision support system that generates individualized advice for asthma patients is provided to the pharmacist/RPht/assistant/student.

Intervention - The Electronic Asthma Management System in Pharmacies (eAMS-Pharm)

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

* Eligible patients would be those who have asthma and are seen at one of the three study pharmacies during the study period * Eligible pharmacy team members would be staff (pharmacists/RPhTs/assistants/students) at any one of the three study pharmacies

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Unity Health Toronto: lead

Study Sites (3)

Medical Place Pharmacy

Ajax, Ontario, L1L 2J5, Canada

Location

LiveWell Pharmacy

Niagara Falls, Ontario, L2J 2K5, Canada

Location

Westmount Place Pharmacy

Waterloo, Ontario, N2L 2R5, Canada

Location

Related Links

• eAMS-Pharm web page

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinician Scientist

Model Details: Interrupted time series analysis

Study Record Dates

• First Submitted: June 5, 2025
• First Posted: June 26, 2025
• Study Start: June 23, 2025
• Primary Completion: December 23, 2025
• Study Completion: January 15, 2026
• Last Updated: August 17, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

CA (3)